Pfizer builds credentials as 'data company'

Pfizer ($PFE) is the world's largest drugmaker, but top executives are making the case that the company really specializes in generating and providing data--albeit data on meds. But the shift in thinking from drug to data company at Pfizer has some potential impacts on how the company does business. For instance, Pfizer has sought new ways to acquire and advance not only drugs but also valuable data. As Craig Lipset, Pfizer's head of clinical innovation, writes on an internal company blog, the company has sought partnerships with companies such as Medco and Humana to improve the use of data in the drug business. Blog

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

The $58 million financing round represents biopharma industry's growing interest in genomics data.

Clinerion inks a new deal that adds 60 million U.S. patients to its clinical trial patient recruitment system.